Official facilitator of

the main

Blood tests can predict breast cancer recurrence

10 July 2019 17:19

Using data from the human immune response, the researchers developed a blood test that can accurately predict the risk of breast cancer recurrence.

Despite the scientific advances in breast cancer research, this type continues to be the leading type of cancer among women in the United States and second in mortality after lung cancer.

For information on how to carry out the treatment of breast cancer in Israel, the best specialists of the country, leave a request and we will contact you shortly.

Many survivors of the constant concern of breast cancer live that disease arises again, while researchers are working hard, trying to identify patterns of recurrence of breast cancer.

For example, breast cancer receptor studies show that breast cancer is negative with respect to the estrogen receptor (ER), are more likely to recur in the first 5 years after diagnosis, while ER-positive breast cancer is associated with a higher risk of relapse over the next 10 year.

Nevertheless, much remains to be learned about the recurrence of breast cancer, and scientists are still trying to understand all the factors that come into play, the nature of the cancer cells to the duration of treatment.

New study examines anti inflammatory response of an organism to develop a blood test that can predict a person's chances soon recurrence of breast cancer.

Dr. Peter P. Lee, head of the department immunoonkologii in Downtown Hope cancer, Duarte, California, is the senior author of the new study, which is published in the journal Nature Immunology.

Predicting risk of relapse within 3-5 years

The balance between pro- and anti-inflammatory immune system transmission signal in response to the cytokines may determine the antitumor immune response explain Dr. Lee and colleagues in his article.

For the study, researchers selected 40 survivors of breast cancer and clinically followed them for an average period of 4 years. The researchers also used an additional sample of 38 survivors of breast cancer, to try to replicate their findings from the previous group.

The researchers explain that the person with cancer, there are regulatory peripheral blood T cells (abbreviated as T-reg) from the less active signaling pathways and proinflammatory cytokines more active immunosuppressive cytokine signaling pathways.

Such an environment can lead to the spread of cancer. So, Dr. Lee and his colleagues studied the signaling responses to pro- and anti-inflammatory cytokines in various types of immune cells of peripheral blood after surviving breast cancer.

The researchers found that signaling response in cells of T-reg has been changed to two pro-inflammatory and anti-inflammatory cytokines two in some survivors of breast cancer.

These signaling responses correlated with the state of the immune system and the participants with accurate predictions of recurrence of breast cancer in the next 3-5 years.

Using these data signaling, scientists have created the index. Health workers hope that they can receive the data of the blood sample from the survivor of breast cancer using an algorithm based on the command signals cytokines transmission index.

The goal is to allow doctors and patients with breast cancer known risk of disease recurrence over the next 3-5 years.

"Knowledge of the likelihood of cancer recurrence, tell your doctor how aggressive should be the treatment of cancer in an individual patient," - explains Dr. Li. "Cytokine signaling Index is a general reflection of the patient's immune system in the diagnosis, which, as we now know, is a major determinant of relapse in the future."

"This is the first success in a solid tumor with biomarker blood - an indicator of whether the patient is in remission."

Dr. Peter P. Lee

The researcher goes on to explain the importance of research and results. "When a patient is first diagnosed with cancer, it is important to identify patients with a higher risk of relapse for more aggressive treatment and monitoring," - he says.

"Staging and new tests based on genomic analysis of the tumor, is currently available for risk stratification. However, the prognostic blood test will be more attractive, but it is not yet available. We are trying to change the status quo."

The researcher also says that "these findings may extend beyond the cancer framework and to address other diseases, which is to fight the immune system", because the balance of the response signals of cytokines between cells T-reg peripheral blood indicates how strong a person's immune system as a whole.

"This general approach can also be useful for predicting outcomes in patients with autoimmune and infectious diseases," - explains Dr. Li.



The form Submitting the this by you agree to the privacy policy


No comments yet

new comment


definitely (will not be published)